Abstract: Various types of nanoparticles, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been employed in targeted therapies for cancer. Both passive and active targeting strategies can be utilized for nanodrug delivery. Passive targeting is based on the enhanced permeability and retention (EPR) effect of the vasculature surrounding tumors. Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed by tumor cells. Release of loaded drugs from nanoparticles may be controlled in response to changes in environmental condition such as temperature and pH. Biodistribution profiles and anticancer efficacy of nano-drugs in vivo would be different depending upon their size, surface charge, PEGylation and other biophysical properties. This review focuses on the recent development of nanoparticles for tumor targeted therapies, including physicochemical properties, tumor targeting, control of drug release, pharmacokinetics, anticancer efficacy and safety. Future perspectives are discussed as well.
INTRODUCTION
Targeted therapies are a major focus of cancer research today. With recent advances of nanotechnology, nanoparticle-based targeted drug delivery, especially for cancer therapies, has attracted increasing attention in the past two decades. Nanoparticles have several advantages for targeted drug delivery. First, they are small in size and can escape the uptake of mononuclear phagocytic system (MPS) cells in the blood and organs. Second, the advantages of tumor targeting and controlled drug release often result in increased therapeutic efficacy of the antitumor agents, and weakened side effects [1] [2] [3] [4] , whereas most free anticancer drugs are taken up nonspecifically by all types of cells, resulting in serious side-effects. In addition, due to their unique size and amenability to surface modification to incorporate the desired characteristics, nanoparticles are particularly well-suited for crossing various biological barriers, such as leaky vasculature.
Nanoparticles used in medicine represent a broad range of materials, including liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide particles, colloidal gold, quantum dot, etc. Liposomes, made of lipids surrounding a water core, are the simplest form of nanoparticles and have been considered as the first type of nanoparticles used as a non-viral gene delivery carrier for therapeutic applications [5] . Polymeric micelles are promising colloidal carriers for targeting poorly water-soluble and amphiphilic drugs as well as genes to tumor tissues [6, 7] . Dendrimers have a very low polydispersity and a defined number of reactive surface groups, which has brought these molecules to the forefront of drug delivery [8] .
Despite the potential advantages, there are limited numbers of nanomedical products for tumor targeted therapies on the market (Table 1) [9] . The majority of products for the treatment of cancer are still in preclinical development, though a few are nearing approval and possible market launch, such as the BLP25 liposome vaccine [10] and Onco TCS (liposomal vincristine) [11] . In this article, recent advances in nanoparticles for tumor targeted therapies, including physicochemical properties, tumor targeting, controlled drug release, pharmacokinetics, efficacy and safety, are reviewed. Dendrimers are built from a starting atom, such as nitrogen, to which carbon and other elements are added by a repeating series of chemical reactions that produce monodisperse macromolecules, with a spherical hyperbranched structure [31] (Fig. (1) ). Unlike linear polymers, the size and molecular mass of dendrimers can be specifically controlled during synthesis. With a hydrophobic core and a hydrophilic surface layer, dendrimers have also been termed unimolecular micelles [32] . But unlike traditional micelles, dendrimers do not have a critical micelle concentration, which offers the opportunity to solubilize poorly-soluble drugs by encapsulating them within the dendritic structure at all concentrations of dendrimer.
Various inorganic materials, such as iron oxide, calcium phosphate precipitates, mesoporous silica, carbon and colloidal gold, can also be used to generate nanoparticles for drug delivery [33] . Inorganic nanoparticles share a typical core/shell structure. The core can contain metals (iron oxide, gold and quantum dots) or organic fluorescent dyes encapsulated in silica. The shell is usually made of metals or organic polymers that protect the core from chemical interactions with the external environment and/or serve as a substrate for conjugation with biomolecules, such as antibodies, proteins and oligonucleotides [34] . Superparamagnetic iron oxide, colloidal gold and quantum dot are three commonly used inorganic nanoparticles (Fig. (1) ). In comparison with organic nanoparticles (liposomes, micelles and dendrimers), inorganic nanoparticles are less biodegradable and have more applications for diagnosis rather than therapies of cancer [35] .
Particle Size and Physical Stability
Nanoparticle size is one particularly important parameters for drug delivery and is believed to impart many of the unique 'nano' medical properties [36] . Although the definition identifies nanoparticles as having dimensions below 100 nm [37] , especially in the area of drug delivery, relatively large nanoparticles (size >100 nm) may be needed for loading a sufficient amount of drugs onto the particles [38] . Generally, the size range of 30-200 nm is preferable, being not only sufficient to avoid leakage into capillaries, but also small enough to avoid the MPS clearance.
Physical stability of nanoparticles is also an important aspect to be considered for clinical applications because the formation of second aggregates of particles may cause blood vessel occlusion and make them more susceptible to clearance by the MPS. Sterically stabilized liposomes can be formulated by modifying the liposomal surface with natural polysaccharides such as mannan and amylopectin [39] or hydrophilic long-chain polymers such as poly(ethylene glycol)(PEG) [40] . Many studies have demonstrated that PEG-modified liposome exhibits its prolonged blood circulating property by reducing the MPS clearance [41, 42] . Physical stability of nanoparticles may be evaluated through determination of the change in particle size of nanoparticles under simulated physiologic conditions including pH, dilution, and interaction with serum proteins. Liu et al., developed a polymeric micelle self-assembled from a folate-conjugated block copolymer [43] . The particle size did not change much in PBS (pH 7.4) either over one week at room temperature (87.0 vs. 97.0 nm), or after 5-fold dilution (87.0 nm vs. 92.1 nm). This is crucial since the dissociation of micelles into individual polymer molecules after administration may lead to rapid release of the enclosed drug, resulting in side effects in vivo. Moreover, the size of the blank micelles remained constant after being challenged by 10% bovine serum albumin (BSA) in PBS (pH 7.4), indicating that the interactions between the micelles and BSA were well-prevented by the hydrophilic shell and negative charges caused by the deprotonation of carboxylic acid groups in the folic acid molecules at pH 7.4. Based on these data, it is expected that the micelles may have good physical stability in vivo.
Surface Characteristics
Surface characteristics contribute to the nanoparticle's solubility, aggregation tendency, ability to traverse biological barriers (such as cell wall), biocompatibility, and targeting ability [19] . In general, the cationic polymers such as polyethylenimine (PEI) and its derivatives [44] , polylysine [45] , polyamidoamine dendrimers [46] , poly(beta-amino esters) [47] , and chitosan [48] are watersoluble and would directly condense DNA in aqueous media, but the stability of the cationic polymer/DNA complexes and their ability to induce sufficient levels of in vivo gene transfection still remain a challenge. Most nanoparticles for drug delivery have a hydrophilic surface to improve solubility. Hydrophilic polymers such as PEG and poly(ethylene oxide) (PEO) have been grafted onto various cationic polymers to improve the stability of the polymers or polymer/DNA complexes [49, 50] . The nanoparticle surface is also responsible for interaction and binding with plasma proteins in vivo, which in turn may alter the nanoparticle's distribution and pharmacokinetics [51, 52] . For multifunctional nanoparticles, modifying agents are often attached to the surface to bind to receptors in target tissues and organs.
Surface charge of nanoparticles may increase nonspecific uptake and clearance by the MPS, making the preparation less effective in targeting [53] . Particles bearing cationic or anionic surface charges have been shown to be more attractive to phagocytes than neutral particles of the same size [54] . The impact of surface charge on pharmacokinetics of nanoparticles will be discussed in detail in section 5.2.
TUMOR TARGETING STRATEGIES 3.1. Passive Targeting Based on the EPR Effect
Passive targeting of nanoparticles relies upon the unique pharmacokinetics of nanoparticles including minimal renal clearance and the "enhanced permeability and retention" (EPR) effect in the tumor. Angiogenesis and vascularization are well-characterized for tumors [55] . In tumors, blood vessel walls become leaky because of defective vascular architecture, including poorly aligned endothelial cells with wide fenestrations and a lack of a smooth muscle layer. These properties result from rapid angiogenesis or vascularization because tumor cells develop so fast and demand a large supply of nutrients and oxygen [56] . The vascular permeability of tumor tissues can also be enhanced by the actions of secreted factors such as kinin and vascular endothelial growth factor [57, 58] . Furthermore, tumor tissues usually lack effective lymphatic drainage. Therefore, macromolecules or leukocytes can be drained through the leaky blood vessels and be retained. This phenomenon was defined as EPR effect [59, 60] . As a result of such increased vascular permeability, polymeric micelles, liposomes, and dendrimers ranging from 50 to 500 nm in size can be selectively delivered to tumor tissue [61, 62] . When these particles are loaded with anticancer drugs, the drugs could be selectively delivered to the tumor tissue ( Fig. (2) (2) ). In contrast, very small nanoparticles (<20-30 nm in diameter) can easily pass through the leaky capillary wall in the tumor but can also be returned to circulating blood by diffusion [63] ( Fig. (2) (1)). Therefore, small particles have good permeability but poor retention. However, after conjugation with a targeting ligand, their retention in the tumor could be greatly enhanced [64] (Fig.  (2)(3) ) (see section 3.2). For tumor targeted drug delivery systems, EPR-effect is now widely accepted as a guiding principle [65] .
Active Targeting
More specific drug targeting can be achieved by binding various ligands to the surface of nanoparticles, such as peptides, growth factors, transferrin, antibodies or antibody fragments such as a single-chain variable fragment (scFv), and small compounds such as folate that can recognize cancer cells (Fig. (2)(3) ). Among these biological signals, antibodies are most promising for their bifunctional properties: both the active targeting potential and anticancer effect by antibody-dependent cell-mediated cytotoxicity (ADCC). The co-delivery of chemotherapeutic drugs and antibody may also sensitize aggressive tumor cells to chemotherapeutic drugs and achieve a synergistic anti-tumor effect [66] . Compared to antibodies, growth factors and peptides, folate is less expensive, more easily conjugated to the nanoparticles, and more stable during transportation, storage and use. More importantly, folate was chosen to be the targeting moiety since folate receptors are vastly overexpressed in carcinomas of the ovary, breast, lung, kidney and brain, but are highly suppressed in normal tissues [67] [68] [69] [70] [71] . Various ligands binding to nanoparticles for active targeting of tumor are listed in Table 2 .
RELEASE OF DRUGS FROM NANOPARTICLES 4.1 Sustained Release and On-Site Release
Nanoparticles have two important advantages in controlled drug release. One is sustained drug release, which mainly results from the dissolution kinetics of nanoparticle core/shell structures and gradual diffusion of the drug localized in the core. Another advantage of nanoparticles is the on-site release, achieved by passive or active targeting strategies. Controlled release of loaded drugs from nanoparticles can maintain the therapeutic dose for an extended period of time and avoid the adverse effects induced by high drug concentration in systemic circulation that are frequent for conventional formulations. For instance, Danhier et al. developed a PEGylated PLGA-based nanoparticle loaded with Cremophor® EL-free paclitaxel. The release behavior of paclitaxel exhibited a biphasic pattern characterized by an initial burst release followed by a slower and continuous release. Paclitaxel released in the first 4 h was equivalent to 46.9±5.7% of the initial drug load of nanoparticles. After 11 days, the amount of accumulated paclitaxel release was 75.3±2.7%. The burst release in the first 4 h may be due to the dissolution and diffusion of the drug that was poorly entrapped in the polymer matrix [87] . Similar burst effect of nano-drugs was observed previously [88, 89] .
Stimuli-Sensitive Polymeric Nanoparticles
More available control of drug release can be achieved by using stimuli-sensitive polymers, which possess active responsiveness to environmental signals, such as surrounding temperature, pH, light, electricity, ionic strength, etc. Among them, temperature and pH may be the two most commonly applied stimuli and have received more attention from researchers.
Temperature Sensitivity
Thermo-sensitive polymers have several advantages when used in drug delivery. First, thermal responsiveness, which relies on local heating to confine the release of drugs, can be applied to a wide spectrum of cancer types, notably improving their clinical applications [90] . Second, hyperthermia also enhances the EPR effect of tumor vasculature, further promoting accumulation of drugs in tumors [91] . In addition, hyperthermia has a particular advantage of being synergistic when combined with chemotherabpy to kill malignant tumor cells [92, 93] . Temperature sensitivity of the polymers originated from the balance between hydrophobic and hydrophilic segments, which can be either monomer units or polymer blocks. Low critical solution temperature (LCST) is a critical physical parameter to evaluate the performance and usefulness of a thermosensitive material. With a narrow temperature increase through the LCST, the polymer undergoes a remarkable phase transition from a water-soluble conformation to an insoluble and hydrophobic aggregate, and the phase transition is reversible corresponding to temperature changes. Poly(N-isopropylacrylamide) (PNIPAAm) is a well-known thermosensitive polymer, exhibiting an LCST of 32°C in water [94] , and has been extensively used as a drug carrier [95] [96] [97] [98] . The LCST can be modulated to be slightly higher than normal body temperature (37°C) in the physiological environment by introducing a hydrophilic monomer (e.g. DMAAm). Liu et al. synthesized a block copolymer, poly(Nisopropylacrylamide-co-N,N-dimethylacrylamide-co-2-aminoethyl methacry-late)-b-poly(10-undecenoic acid) (P(NIPAAm-coDMAAm-co-AMA)-b-PUA). At pH 7.4, the LCST was 38.0 °C, well above normal body temperature [43] . Yang et al. constructed a block copolymer, (poly(N-isopropylacrylamide-co-acrylamide)-bpoly (DL-lactide)), which can form micelle structures in aqueous media. The LCST of the micelles was increased to 41°C, which made the micelles exist as a highly soluble form at physiological temperature. Further, they found hyperthermia greatly enhanced the efficacy of docetaxel-loaded micelles, demonstrating the temperature sensitivity of drug release from micelles [99, 100] .
pH Sensitivity
pH-responsive polymeric drug carriers have also received a great deal of attention and a number of them have been developed in recent years. The extracellular pH in most solid tumor tissues ranges from 5.7 to 7.8 [101] , while the intracellular pH, especially in acidic endosomes or lysosomes, ranges from 5.0 to 6.5. Based on the distribution property of pH in the tumor microenvironment, nanoparticles can be designed to release the loaded drugs at the tumor site either extracellularly or intracellularly, after cellular uptake of the drug-polymer conjugate [102] [103] [104] . Lee et al. reported a core-shell nanoparticle made from poly(L-histidine)-block-PEG, which can dissociate at pH 7.0 to 7.4, thereby releasing the enclosed doxorubicin extracellularly [105] . PbAE possesses the pHdependent solubility characteristic and is suitable for the fabrication of drug delivery systems that can be used to trigger or enhance the intracellular release of the payload upon exposure to acidic endosomal vesicles. Solid unprotonated samples of the PbAE are insoluble at physiological pH (7.4) [106] , but become instantly soluble in aqueous media when the pH of the solution is reduced below 6.5 [107] . Because the transition from solid preparation to dissolved material occurs over the range of extracellular and endosomal/lysosomal pH (7.4 and 5.0-6.5 respectively), these polymers may be useful for the delivery of therapeutic agents in the vicinity of a tumor mass and for others that must escape endosomal compartmentalization prior to fusion with lysosomes. Wang et al. developed a targeted delivery system, by in situ functionalization of a polymerisable pH-sensitive amphiphilic surfactant, N-(1-aminoethyl)-iminobis-[N-(oleicyl-cysteinyl-histinyl-1-aminoethyl) propionamide] (EHCO) and self-assembly with siRNA. The intrinsic pH-sensitive amphiphilicity of EHCO at pH 5-6 was able to induce cell membrane disruption at endosomal pH and facilitate endosomal escape of the siRNA nanoparticles after internalization. Flow cytometric analysis of cellular uptake and gene silencing efficiency showed that free siRNA exhibited poor efficiency for both gene silencing (4.5 ± 0.3%) and cellular uptake (1.7 ± 0.3%), while EHCO/siRNA was highly efficient and resulted in 84.2% ± 0.8% cellular uptake and 86.9 ± 0.5% gene silencing [108] .
Combination of Temperature-and pH-Sensitivity in One Nanoparticle
Combination of temperature-sensitivity with sensitivity to another stimulus such as pH would increase the control precision of drug release of nanoparticles. Seow et al. designed a polymeric micelle which has a lower LCST that can respond to the pH of the external environment in an adjustable fashion. In environments that are characteristically more acidic, the LCST of the micelles dropped below 3 , resulting in both the disruption of the coreshell architecture and the release of drug [108] . Soga et al. constructed biodegradable micelles with thermosensitive polymers, poly(N-(2-hydroxypropyl) methacrylamide lactate) (poly (HPMAm-lactate)). The micelles can load paclitaxel up to 2 mg/mL and release relatively high concentrations of paclitaxel induced by pH-dependent destabilization [109] . Liu et al. utilized biofunctional block copolymer folate-conjugated poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide-co-2-aminoethyl methacrylate)-b-poly(undecenoic acid) to fabricate micelles for targeted delivery of doxorubicin. The micelles were pH-and temperaturesensitive, from which doxorubicin release was much faster at pH 6.6 when compared to of its release at pH 7.4, with a release rate of approximately 85% and 40%, respectively, within 24 h. At pH 6.6, the LCST of polymer decreased to 36.2 °C, leading to hydrophobicity in the shells of the micelles. The loss of the hydrophilictiy/hy drophobicity balance of the micelles resulted in the eventual deformation of the core-shell structure, releasing the enclosed drug molecules [45] . Other stimuli such as light, electricity and ionic strengthresponsive nanoparticles are also under study. Research into lightresponsive nanoparticles has been focused mainly on selfassembled colloids such as copolymer micelles and liposomes [100] . Light-responsive polymeric micelles are usually selfassembled from amphiphilic block polymers. Wang, et al. developed a polymeric micelle with reversible light-responsive dissociation and formation. The micelle is assembled from amphiphilic diblock copolymers composed of a hydrophobic side-chain liquid crystalline azobenzene polymethacrylate and a hydrophilic poly(acrylic acid). When the micellar solution is exposed to UV light, the micelles dissociate. But this can be reversed with exposure to visible light [111] . With electro-sensitive polyelectrolyte or poly(vinyl alcohol) hydrogels, pulsed drug release profiles may be achieved in response to alternating application and removal of the electric field [112, 113] . Micelles exhibiting responsive behavior to ionic strength of the solution can also be designed with amphiphilic block copolymers, and may be used in controlled drug release [114, 115] .
PHARMACOKINETICS
There are many factors that influence the uptake and biodistribution of nanoparticles in vivo, mainly including particle size, surface charge and functionalization, permeability of blood vessels, and phagocytosis by the MPS.
Impact of Particle Size on Pharmacokinetics of Nanoparticles
Particle size plays a key role in the biodistribution of nanoparticles. Blood vessels are responsible for delivering molecules to organs throughout the body; therefore the capillary endothelium becomes the primary biological barrier. Tissues with a leaky endothelial wall, such as tumors, liver, spleen, and bone marrow, usually experience significant uptake of nanoparticles. As mentioned above, angiogenesis and vascularization are two characteristic properties of tumors that result in defective hypervasculature, which has given rise to the EPR effect. Through the EPR effect-mediated passive targeting, drug-loaded nanoparticles (generally 50-200 nm in diameter) preferentially accumulate and diffuse in tumor tissues.
In liver, spleen and bone marrow, the capillary endothelium is commonly discontinuous, with numerous fenestrae of up to 150 nm [116] [117] [118] [119] . Moreover, the basal membrane in sinusoidal capillaries is either absent (e.g. in liver) or present as a discontinuous membrane (e.g. in spleen and bone marrow) [120] . After administration, nanoparticles can be rapidly taken up by the liver, spleen, and bone marrow. Generally, very small particles with dimensions of less than 5-10 nm are rapidly eliminated by renal excretion [121] . Particles with diameter between 150-300 nm are found mainly in the liver and the spleen [122] , whereas particles with diameter between 30-150 nm are located in bone marrow, heart, kidney and stomach [123] . In addition to the discontinuous capillary endothelium, the enhanced uptake in the liver, spleen, and bone marrow is also attributed to the MPS cells present in the tissues, which are responsible for clearing particulates and macromolecules circulating in the blood [64] . The general correlation of biodistribution and elimination with respect to size may vary greatly depending on nanoparticle surface characteristics.
Impact of Active Targeting and Surface Charge on Pharmacokinetics of Nanoparticles
Active targeting is designed to increase accumulation and distribution of therapeutic drugs at targeted sites, through the specific interaction of ligands with the corresponding receptors overexpressed on target cells. Saad et al. compared the pharmacokinetics of three different types of targeted or non-targeted nanocarriers (linear polymer, dendrimer and liposome) in mice. These nanocarriers were loaded with the anticancer drug paclitaxel and the imaging agent Cy5.5, non-targeted or targeted with an analog of luteinizing hormone-releasing hormone (LHRH) peptide as a cancer targeting moiety. They found that targeted delivery to LHRH receptoroverexpressed tumor cells significantly changed the biodistribution of nano-drugs, increased the accumulation in tumor tissues and decreased the build up in healthy organs. However, significant amounts of non-targeted nanocarriers were found in healthy organs, mainly in the liver, spleen and kidney [124] . Tseng et al. evaluated the distribution of GP-Av-bEGF in normal and tumor-bearing mice at 0.5 and 24 h after inhalation by detecting the fluorescence intensity, and found that the accumulation of nanoparticles in the cancerous lungs was 3.6-fold higher than that of the normal lungs, indicating that GP-Av-bEGF was able to specifically target EGF receptor-overexpression lung cancer cells [76] . Temperaturesensitive drug release from nanoparticles, also considered as a targeting strategy in some occasions, enabled a prominent higher drug concentration in tumor than conventional formulation, consequently with a significantly higher antitumor efficacy in mice when accompanied by hyperthermia [99] .
Surface charge of nanoparticles can also affect their uptake by the MPS. Studies have shown that positively charged nanoparticles have a higher rate of cell uptake when compared to neutral or negatively charged formulations [125] . Positively charged particles are able to form aggregates in the presence of the negatively charged serum proteins once administered intravenously. [126] . These aggregates are usually large and may cause transient embolism in the lung capillaries. Subsequently, the dissociated particles redistribute to the liver. Thus, positively charged nanoparticles often exhibit a rapid blood clearance with a significant accumulation in the lung and liver, whereas neutral or negatively surface charged nanoparticles have a reduced plasma protein adsorption and low rate of nonspecific cellular uptake [53] . Addition of polymer coatings such as PEG, poloxamer, and poloxamine to the nanoparticle surface is a useful tool for effectively neutralizing the cationic surface charge, and subsequently decreasing nonspecific uptake by the MPS [127] [128] [129] . Among these polymers, PEG is the mostly commonly used in formulations and will be discussed in detail in the following section.
Opsonization and Its Solution by PEGylation of Nanoparticles
When nanoparticles are introduced into the circulatory system, a variety of serum proteins bind to the surface of the nanoparticles, which are recognized by the scavenger receptor on the MPS cell surface and internalized, leading to a significant loss of nanoparticles from the circulation [130, 131] . This process is defined as "opsonization", and the serum proteins binding on the nanoparticles are termed "opsonins". The opsonization of nanoparticles by the MPS is a major obstacle that hinders the efficiency of the nanoparticulate drug delivery systems. Minimizing protein binding is the key point for developing a long circulation nanoparticle formulation.
Surface attachment of certain polymers such as PEG or PEO may prevent nanoparticles from being uptaken by mononuclear phagocytes in the liver, spleen, and lymph nodes, thereby improving accumulation in the tumor, and minimizing opsonization [132] . Among them, PEGylation is the most commonly used strategy, as reviewed by Owens et al. [133] . PEG is a relatively inert hydrophilic polymer that provides good steric hindrance for preventing protein binding [134] . PEGylation refers to the decoration of a particle surface by the covalently grafting, entrapping, or adsorbing of PEG chains. In the case of biodegradable nanoparticles, PEG chains can be incorporated as copolymers throughout the particle so that some surface PEG chains are always available even after the degradation of surface layers. A number of studies have shown that PEGylation efficiently reduces nonspecific interactions with proteins through its hydrophilicity and steric repulsion effects, consequently reduces opsonization and increases the circulatory residence time for various types of nanoparticles, including liposomes [135] , polymeric micelles [136] , dendrimers [137] , gold nanoparticles [138] , etc. Particularly, PEG polymers have low toxicity and almost no immunogenicity, and have been approved by the Food and Drug Administration (FDA) for clinical use. Although several materials have been developed to mimic the effect of PEG for reducing the degree of opsonization [139] [140] [141] , PEGylation is still the most commonly used approach.
Taking the advantage of its ability to block the adhesion of opsonins present in the blood serum, PEGylation has been extensively applied to impart stealth to nanoparticles and prolong the circulation half-life of nanoparticles and encapsulated drugs [142] [143] [144] . For instance, Senthilkumar et al. have demonstrated that PEGylated nanoparticle formulations exhibited a markedly delayed blood clearance, and the blood concentration remained very high even 24 h after administration. In contrast, the DTX solution and PLGA nanoparticle formulations were quickly eliminated from circulation and their blood concentrations at 2 h after administration were very low [145] . Liu et al. reported that PEG could be used to wrap single-walled carbon nanotubes (SWNTs) to escape the capture by MPS for a blood circulation half-life of up to two hours [146] . Sadzuka et al. investigated the pharmacokinetics (PK) of the encapsulated drugs formulated in either plain liposomes or PEGylated liposomes. The AUC of the blood PK profile of the drug formulated in the PEGylated liposomes was 6-fold higher than that of the non-PEGylated formulation and 36-fold higher than that of the free drug. The rate of MPS uptake in the liver for the drug encapsulated in the non-PEGylated liposomes was 3-fold higher than that of the PEGylated formulation, which resulted in a 3-fold higher rate of tumoral uptake for the drug encapsulated in the PEGylated liposomes than that of the non-PEGylated liposomes. The increased level of tumoral accumulation of the PEGylated formulation was correlated with antitumor efficacy superior to that of the free drug as well as the drug formulated in the non-PEGylated liposomes [147] .
The chain length, shape, total molecular weight and density of PEG on the particle surface have been shown to be the main parameters affecting nanoparticle surface hydrophilicity and phagocytosis. Kaminskas et al. investigated the impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-Lysine dendrimers, and found that the volumes of distribution, clearance and consequently the plasma half-lives of the PEGylated dendrimers were markedly dependent on the total molecular weight of the PEGylated dendrimer, but were not specifically affected by the PEG chain length alone [148] .
EFFICACY AND SAFETY 6.1. Antitumor Efficacy and Side Effects of Drug-Loaded Nanoparticles
Anticancer drugs delivered by nanoparticles achieved increased antitumor efficacy compare with free drugs in a number of investigations, due to the improved biodistribution of drugs and reduced side effects. For example, in a study conducted by Saad et al. [124] , compared with non-targeting delivery system, LHRH receptorbased targeting delivery significantly enhanced the antitumor activity of drugs in nude mice bearing A549 xenografts tumors. Meanwhile, this targeting delivery reduced adverse effects of the treatment in healthy organs. In addition, even non-targeted drug delivery of paclitaxel using nanocarriers was significantly more effective in inhibiting tumor growth than free drug. More importantly, among three different types of nanoparticles (linear polymer, dendrimer and PEGylated liposome), PEGylated liposome was most effective in suppression of tumor growth in animal models, which may be attributed to reduced opsonization in vivo by PEGylation [124] . In another study, mice were more sensitive to the antitumor effect of paclitaxel-loaded nanoparticles and exhibited higher survival rates when compared to paclitaxel alone. On the other hand, the nanoparticle formulations of paclitaxel allowed us to reduce the use of Cremophor® EL which may cause serious adverse effects [87] . In conclusion, tumor-specific targeting delivery of nanoparticles could increase the antitumor therapeutic efficacy while lowering side effects on healthy organs.
Co-Delivery
An important application of nanoparticles in drug delivery is to co-deliver multiple therapeutic agents such as small molecule drugs, genes, peptides/proteins, etc., in a single particle by construction of multifunctional nanoparticles. Co-delivery of drugs and DNA has been proposed to enhance gene expression or to achieve the synergistic effect between drug and gene therapies [149] [150] . For example, in a study reported by Wang, Y. et al., the tumor growth rate in mice treated with paclitaxel-loaded nanoparticle/IL-12-encoded plasmid complexes was significantly lower than that observed in mice treated with either paclitaxel-loaded nanoparticles or nanoparticle/IL-12 gene complexes, suggesting a significant synergistic/combined effect of co-delivery of paclitaxel and the IL-12 gene [151] . Co-delivery of chemotherapeutic drugs and antibody by a nanoparticle may confer upon the delivery system both an active targeting ability and the possibility of sensitizing aggressive tumor cells to chemotherapeutic drugs, thus achieving a synergistic anti-tumor effect. In preclinical studies [152, 153] , as well as phase II and III clinical trials [154, 155] , synergistic chemosensitization effects have been observed with co-treatments of Herceptin and paclitaxel. In these formulations, paclitaxel and Herceptin have been administered through separate injections, while in the study reported by Lee et al., paclitaxel and Herceptin were delivered simultaneously with a cationic P(MDS-co-CES) micelle. This codelivery approach confers greater advantages over the separated formulations because of the reduction in the number of injections and the possibility of achieving a synergistic effect. Cytotoxicity data based on BT474 cells with high level Her2-expression showed that cell viability is reduced to 60.2% after being treated with paclitaxel-loaded nanoparticle/Herceptin complexes (Herceptin: 200 nM; paclitaxel: 6.7 mM) as compared to 92% with 200 nM Herceptin alone or 83% with paclitaxel-loaded nanoparticles, demonstrating a synergistic effect [66] . Another example of nanoparticles for co-delivery is a vaccine based on PLGA nanoparticles coencapsulating the poorly immunogenic melanoma antigen, tyrosinase-related protein 2 (TRP2), along with Toll-like receptor (TLR) ligand (7-acyl lipid A), (TRP2/7-acyl lipid A-NP), reported by Hamdy et al. They found that activated TRP2-specific CD8 T cells were capable of interferon (IFN)-secretion at lymph nodes and spleens of the vaccinated mice. More importantly, the above co-delivery of agents was demonstrated to be effective in inducing immunostimulation at the tumor microenvironment, as evidenced by decreased levels of VEGF and elevated levels of IL-2, IL-6, IL-12, IFN-and TNF-. compared to the control group [156] .
Multidrug-resistance (MDR) is a major obstacle that limits the success of cancer therapy. Multifunctional nanoparticles that could simultaneously deliver multiple therapeutic agents and release active components with a comparable profile may be a promising solution for treatment of MDR tumors. Two main mechanisms are responsible for MDR: pump and nonpump resistance [157] . Pump resistance is caused by membrane efflux pumps that decrease the anticancer-drug concentration inside the cells. Nonpump drug resistance is attributed primarily to the mechanisms responsible for the activation of anti-apoptotic cellular defense [158, 159] . Many types of human MDR cancers activate both pump and nonpump resistance in response to treatment with anticancer drugs. Therefore, simultaneous suppression of both types of cellular resistance is required for substantial enhancement of the treatment efficacy. Based on this concept, Saad et al. developed a multifunctional nanoparticle-based delivery system, which contains the following components: 1) cationic liposomes as a carrier; 2) doxorubicin as a cell-death inducer; 3) siRNA targeted to MRP1 mRNA as a suppressor of drug-efflux pump in small cell lung cancer (SCLC) cells; 4) siRNA targeted to BCL2 mRNA as a suppressor of celluar antiapoptotic defense. Their results showed that cationic liposomes were able to co-deliver siRNA and doxorubicin efficiently into MDR lung cancer cells. Simultaneous delivery of suppressors of pump and nonpump resistance in combination with the anticancer drug led to effective apoptosis induction and killing of drugresistant lung cancer cells [160] .
Safety of Nanoparticles
With the extensive investigation of nanoparticles in medicine, safety issues of nanomaterials are receiving increased focus and attention. Most of the nanoparticles for drug delivery were reported non-toxic in vivo, especially those synthesized from biodegradable polymers [103, 161] . However, toxicities of nanoparticles have also been reported [162, 163] . Though transient inflammation might be considered a lesion induced by host defense mechanisms and negligible for determining the toxicity of nanoparticles, the apoptosis and cumulative property of PEG-coated gold nanoparticles was clearly considered as toxicity [164] [165] [166] .
The main molecular mechanism of in vivo nanotoxicity is the induction of oxidative stress by free radicals, originating from phagocytic cell response to foreign nanomaterials, as reviewed by Lanone and Boczkowski [167] . Free radicals may cause damage to biological components through oxidation of lipids, proteins, and DNA. Oxidative stress may have a role in the induction or the enhancement of inflammation through upregulation of redox sensitive transcription factors, activator protein-1, and kinases involved in inflammation [168] . Slow clearance and tissue accumulation of nanomaterials in the organs of the MPS makes organs such as the liver and spleen the main targets of oxidative stress. Additionally, organs of high blood flow that are exposed to nanomaterials, such as the kidneys and lungs, can also be affected. Intracellularly, nanomaterials may be capable of localizing to mitochondria and inducing apoptosis and reactive oxygen species (ROS) formation, which are possible sources of toxicity [169] .
Studies on tissue distribution, acute inflammatory responses, and histopathological changes in vivo are needed to determine whether these nanoparticles are indeed safe. In addition, long-term toxicity of the materials and examination of chronic exposure are critical to understanding the toxicology of nanomaterials in vivo [170] . Careful scrutiny of the in vivo and in vitro toxicities of nanoparticles is required even for materials that have been previously shown to have limited or no toxicity at the cellular level.
CONCLUSION AND FUTURE PERSPECTIVES
Nanoparticals can accomplish tumor targeted drug delivery via passive targeting based on the EPR effect, or active targeting by conjugated ligands, such as antibodies, folates and peptides. Drug release from nanoparticles becomes more controllable by utilization of temperature-and/or pH-sensitive polymers. Targeted delivery of nano-drugs significantly increases the accumulation and distribution of therapeutic drugs in tumor mass, with improved antitumor efficacy and reduced side effects on healthy tissues. Multifunctional nanoparticles are developed to co-deliver multiple components in a single particle, producing synergistic anti-tumor interactions, thus showing unique promise in cancer treatment. Physical and chemical properties, including size, charge, and surface chemistry (e.g. PEGylation), greatly influence the pharmacokinetics and the tissue distribution of nanoparticles. The production of free radicals and subsequent oxidative stress is considered as the main mechanism of nano-toxicity.
In general, nanoparticle-based tumor targeted therapies appear to be very promising for the innovation of cancer therapy. Based on the development status and retained challenges, the following aspects may be part of potential future directions. 1) Development of multifunctional nanopaticles containing specific ligand for active targeting, and more than one drug for synergistic anticancer effects or treatment of multidrug-resistant cancer; 2) Control of drug release from nanoparticles. This may be another major research direction since only released drug is bioavailable. If the drug release can be controlled locally in the target tissues, the tissue penetration problem may no longer be a critical issue, especially for small molecular drugs; 3) Solution of opsonization. As drug-loaded nanoparticles are quite complex, many unexpected interactions with biological components may arise. Better solutions than PEGylation may be needed to decrease further the uptake of nanoparticles by MPS cells, which would result in decreased accumulation of nanoparticles in liver, spleen and marrow; 4) Safety studies. As nanoparticle toxicology is a relatively young field, some nanomaterials previously considered biocompatible may indeed be toxic. More systemic data is needed before they are used in clinical practice. 
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